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Non-Dipper Status and Left Ventricular Hypertrophy as Predictors 
of Incident Chronic Kidney Disease 
We have hypothesized that non-dipper status and left ventricular hypertrophy (LVH) are 
associated with the development of chronic kidney disease (CKD) in non-diabetic 
hypertensive patients. This study included 102 patients with an estimated glomerular 
filtration rate (eGFR) ≥ 60 mL/min/1.73 m
2. Ambulatory blood pressure monitoring and 
echocardiography were performed at the beginning of the study, and the serum creatinine 
levels were followed. During the average follow-up period of 51 months, CKD developed 
in 11 patients. There was a significant difference in the incidence of CKD between dippers 
and non-dippers (5.0% vs 19.0%, P < 0.05). Compared to patients without CKD, patients 
with incident CKD had a higher urine albumin/creatinine ratio (52.3 ± 58.6 mg/g vs 17.8 ± 
29.3 mg/g, P < 0.01), non-dipper status (72.7% vs 37.4%, P < 0.05), the presence of LVH 
(27.3% vs 5.5%, P < 0.05), and a lower serum HDL-cholesterol level (41.7 ± 8.3 mg/dL vs 
50.4 ± 12.4 mg/dL, P < 0.05). Based on multivariate Cox regression analysis, non-dipper 
status and the presence of LVH were independent predictors of incident CKD. These 
findings suggest that non-dipper status and LVH may be the therapeutic targets for 
preventing the development of CKD in non-diabetic hypertensive patients.
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INTRODUCTION
Chronic kidney disease (CKD) is emerging as a worldwide public 
health problem because of the rising prevalence and incidence. 
Although early detection and therapeutic interventions may slow 
or prevent the progression toward renal failure and the associ-
ated complications, CKD is usually under-diagnosed and un-
der-treated, resulting in unfavorable outcomes (1, 2). One of the 
reasons is thought to be an under-recognition of the earlier stag-
es of CKD and risk factors for CKD.
  Among the commonly considered risk factors for the devel-
opment of CKD such as age, diabetes, hypertension, vascular 
disease, and ethnicity (3), diabetes is known to be the strongest 
determinant (4). In non-diabetic patients, however, it appears 
that predictors of incident CKD have not been well elucidated. 
  There are tremendous evidences for proving that the night-
time blood pressure (BP) is the more powerful predictor in car-
diovascular morbidity and mortality than conventional office 
and ambulatory daytime BP (5). In healthy subjects, there is a 
diurnal variation in BP which decreases by 10%-20% during the 
nighttime compared to the daytime. Patients without a noctur-
nal BP decline ≥ 10% of daytime values are referred to as non-
dippers (6). 
  The rate of decline in the glomerular filtration rate (GFR) is 
faster in hypertensive patients with blunted diurnal BP varia-
tion (7). In addition, the non-dipping phenomenon in end-stage 
renal disease (ESRD) patients is closely related to a high inci-
dence of cardiovascular disease and a poor long-term survival 
(8). Therefore, it has become important to observe 24-hr ambu-
latory blood pressure monitoring (ABPM) patterns, including 
blunting or loss of diurnal variation, in hypertensive and CKD 
patients. 
  Left ventricular hypertrophy (LVH) is regarded as a common 
target organ damage of hypertension (9). Moreover, LVH is asso-
ciated with an increased incidence of cardiovascular events (10). 
In CKD patients, LVH is more prevalent and more severe than 
in hypertensive patients with normal renal function (11), and 
accompanied by increased cardiovascular mortality, even in pa-
tients with mild renal dysfunction (12). Furthermore, it was re-
cently reported that LVH is a predictor of subsequent renal dys-
function in men with high cardiovascular risk (13). 
  However, there is little evidence that the non-dipping pattern An HR, et al.  •  Non-Dipper and LVH as Predictors of Incident CKD
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of nocturnal BP or LVH is associated with the development of 
CKD in hypertensive patients with preserved renal function. In 
the present study, we determined whether or not non-dipper 
status and LVH are predictors of incident CKD in non-diabetic 
hypertensive patients treated with antihypertensive medications.  
MATERIALS AND METHODS
Subjects
We conducted the analysis using a retrospective cohort. This 
study included patients with essential hypertension recruited 
for a cross-sectional study, the precise methods have been de-
scribed elsewhere (14). Briefly, participants were between 30 
and 80 yr of age with essential hypertension and treated with an-
tihypertensive drugs for at least 1 yr. The exclusion criteria were 
a history of diabetes mellitus or a fasting blood glucose > 126 mg/ 
dL at the time of enrollment to the study, any previous cardio-
vascular events, a history of liver cirrhosis, inflammatory disease, 
and a random urine albumin/creatinine ratio (ACR) of ≥ 300 
mg/g, and use of various confounding medications. The patients 
were followed and antihypertensive medications were individu-
alized to each subject, and were changed ad libitum on the ba-
sis of the clinician’s decision during the follow-up period. In this 
cohort, we selected participants with an estimated GFR (eGFR) 
which was > 60 mL/min per 1.73 m
2 at the time of enrollment, 
as determined by the abbreviated Modification of Diet in Renal 
Diseases (MDRD) formula (15), and in whom serum creatinine 
levels were followed ≥ 3 times until the time of the analysis. We 
finally enrolled 102 subjects in the current study. Incident CKD 
was defined as an eGFR decreased to < 60 mL/min/1.73 m
2 per-
sisting for at least 3 months.
  At the beginning of the study, patients underwent a complete 
physical examination, demographic and laboratory assessments, 
24-hr ABPM, and a baseline electrocardiogram. The following 
laboratory parameters were performed: blood chemistries; high 
sensitivity C-reactive protein (hsCRP); and random urine anal-
ysis for urine ACR. 
BP monitoring 
Office BP was measured in the outpatient clinic, using a sphyg-
momanometer after at least 5 min of rest in a sitting position. 
Two blood pressures were measured at least 5 min apart and 
the mean BP was used for analysis. 
  Twenty-four-hour ABPM was performed using a Takeda TM-
2421 (A&D Medical, Tokyo, Japan). The daytime BP recording 
was done every 30 min from 7 AM to 11 PM and the nighttime 
BP recording was done every 30 min from 11 PM to 7 AM. 
  The recordings for 24 hr were then analyzed to obtain daytime 
and nocturnal average systolic BP (SBP) and diastolic BP (DBP). 
Nocturnal BP dipping was defined as ≥ 10% decrease in noctur-
nal SBP and DBP compared to the average daytime SBP and DBP. 
Patients with < 10% decrease or increase more than the daytime 
BP in the nighttime BP were considered to be non-dippers in 
this study. Nocturnal hypertension was defined as an average 
nocturnal BP > 125/75 mmHg.
Echocardiography
Echocardiography was performed with an ultrasound system 
(Vivid 7 GE Vingmed, Horten, Norway) with a 2.5 MHz trans-
ducer and interpreted by two experienced readers blinded to 
the clinical information. Standard two-dimensional parameters 
were measured with the patient in the left lateral position. The 
left ventricular (LV) ejection fraction was calculated. To evaluate 
LV filling pressures, the ratio mitral inflow peak velocity (E)/ear-
ly diastolic tissue velocity of the mitral annulus (E’) was calculat-
ed. LV mass was determined by the method of Devereux et al. 
(16), with the LV mass index calculated by dividing the LV mass 
by the body surface area. Men with a LV mass index > 125 g/m
2 
and women with a LV mass index > 100 g/m
2 were considered 
to have LVH.
Statistical analysis
Statistical analysis was performed with SPSS 16.0 (SPSS Inc, Chi-
cago, IL, USA). The continuous variables are presented as the 
mean ± standard deviation, or patient number (%). The differ-
ences between any two groups were evaluated by a chi-square 
test for categorical data and Student’s t-test for continuous vari-
ables. To investigate the predictors of the development of CKD, 
Cox proportional hazard analysis was performed. Any difference 
was considered significant when a P value was < 0.05.
Ethics statement
This study was approved by the institutional review board of 
Severance Hospital, Yonsei University Health System, Seoul, 
Korea (IRB approval number: 4-2011-0187). The board waived 
submission of informed consent.
RESULTS
Baseline characteristics of the study populations
The baseline characteristics and BP measurements of the study 
populations are shown in Table 1. The mean age of the patients 
was 56.0 ± 10.4 yr and the mean duration of hypertension was 
93.6 ± 36.1 months. Based on the 24-hr ABPM data, the mean 
fulltime SBP and DBP were 125.8 ± 14.0 mmHg and 78.6 ± 9.2 
mmHg, respectively. The mean initial eGFR was 81.4 ± 16.1 mL/ 
min/1.73 m
2, and the mean initial urine ACR was 21.1 ± 34.2 
mg/g.
Comparisons between dippers and non-dippers
When the study population was divided into dippers and non-
dippers based on the 24-hr ABPM results, 42 of 102 patients were An HR, et al.  •  Non-Dipper and LVH as Predictors of Incident CKD
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classified as non-dippers. There were no significant differences 
in age, body mass index (BMI), and the duration of hyperten-
sion between the two groups. However, the non-dippers dem-
onstrated lower proportion of males (46.7% vs 26.2%, P < 0.05) 
and higher office SBP (130.2 ± 17.7 mmHg vs 139.0 ± 22.9 mmHg, 
P < 0.05) compared to the dippers. The data from the 24-hr ABPM 
were not significantly different in the mean fulltime BP and mean 
daytime BP between the two groups, while the mean nighttime 
BP (SBP, 111.5 ± 11.1 mmHg vs 123.7 ± 17.8 mmHg, P < 0.001; 
DBP, 69.5 ± 7.7 mmHg vs 75.0 ± 9.4 mmHg, P < 0.01) and pulse 
pressure (42.0 ± 7.4 mmHg vs 48.7 ± 13.6 mmHg, P < 0.01) were 
significantly higher, and the nocturnal hypertension was more 
prevalent in the non-dippers (25.0% vs 61.9%, P < 0.001; Table 
2). Between the two groups, there were no significant differenc-
es in laboratory findings including initial eGFR and urine ACR. 
In addition, there were no significant differences in the LV ejec-
tion fraction, whereas parameters which indicate LV diastolic 
dysfunction such as left atrial (LA) volume index (20.5 ± 5.2 mL/ 
m
2 vs 24.3 ± 7.3 mL/m
2, P < 0.01) and E/E’ (9.65 ± 2.29 vs 12.42 ± 
3.88, P < 0.001), and the presence of LVH (3.3% vs 14.3%, P < 0.05) 
were higher in the non-dippers (Table 3).  
Follow-up of renal function
During the average follow-up period of 51 months (range, 13-
64 months), there were no differences in BUN, creatinine, and 
eGFR between the dippers and non-dippers. Although the an-
nual change rate of the eGFR showed no significant differences 
(-0.20 ± 6.59 mL/min/1.73 m
2/year vs -1.36 ± 4.68 mL/min/1.73 
m
2/yr, P = 0.303), the incident CKD patients whose eGFR was 
reduced to < 60 mL/min per 1.73 m
2 and persisted for at least 3 
months were more frequently observed in the non-dippers (5.0% 
vs 19.0%, P < 0.05).
Comparisons between patients with newly developed CKD 
and without CKD
The decline rate of the eGFR was significantly higher in patients 
with incident CKD than in patients without CKD (-4.38 ± 4.67 
mL/min/1.73 m
2/yr vs -0.23 ± 5.88 mL/min/1.73 m
2/yr, P < 0.05). 
There were no significant differences in age, gender, BMI, dura-
tion of hypertension, duration of follow-up, office BP, and all pa-
rameters on 24-hr ABPM between patients with newly developed 
Table 1. Baseline characteristics of participants
Parameters Total (n = 102)
Age (yr)    56.0 ± 10.4
Male (No. [%])  39 (38.2)
BMI (kg/m
2)  25.5 ± 2.9
HTN duration (months)    93.6 ± 36.1
Office SBP (mmHg)  133.8 ± 20.4
Office DBP (mmHg)    82.9 ± 11.9
Mean fulltime SBP (mmHg)  125.8 ± 14.0
Mean fulltime DBP (mmHg)  78.6 ± 9.2
Daytime SBP (mmHg)  130.3 ± 14.7
Daytime DBP (mmHg)    82.0 ± 10.2
Nighttime SBP (mmHg)  116.5 ± 15.4
Nighttime DBP (mmHg)  71.8 ± 8.9
Initial eGFR (mL/min/1.73 m
2)    81.4 ± 16.1
Urine ACR (mg/g)    21.1 ± 34.2
Antihypertensive medications, No. (%)
   ACE inhibitors
   Angiotensin II receptor blockers
   Beta blockers
   Calcium channel blockers
   Diuretics
  
17 (16.7)
45 (44.1)
39 (38.2)
64 (62.7)
43 (42.2)
No. of antihypertensive medications   2.0 ± 0.9
BMI, body mass index; HTN, hypertension; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; eGFR, estimated glomerular filtration rate; ACR, albumin/creatinine 
ratio.
Table 2. Comparisons of initial demographic and clinical characteristics between dip-
pers and non-dippers
Characteristics Dippers  
(n = 60)
Non-dippers  
(n = 42)
P value
Age (yr) 54.7 ± 11.2 57.8 ± 9.1 0.134
Male (No. [%])  28 (46.7) 11 (26.2) < 0.05
BMI (kg/m
2)  25.6 ± 3.2 25.5 ± 2.5 0.896
HTN duration (months)    94.7 ± 39.1   91.9 ± 31.7 0.688
Office SBP (mmHg)  130.2 ± 17.7 139.0 ± 22.9 < 0.05
Office DBP (mmHg)    82.1 ± 12.1   84.1 ± 11.8 0.403
Mean fulltime SBP (mmHg)  125.2 ± 12.2 126.7 ± 16.4 0.595
Mean fulltime DBP (mmHg)  79.0 ± 8.6   78.1 ± 10.1 0.633
Mean daytime SBP (mmHg)  131.6 ± 13.5 128.6 ± 16.2 0.310
Mean daytime DBP (mmHg)  83.5 ± 9.4   80.0 ± 11.0 0.084
Mean nighttime SBP (mmHg)  111.5 ± 11.1 123.7 ± 17.8 < 0.001
Mean nighttime DBP (mmHg)  69.5 ± 7.7 75.0 ± 9.4 < 0.01
Mean nighttime pulse pressure  42.0 ± 7.4   48.7 ± 13.6 < 0.01
Mean night BP > 125/75 mmHg  
   (No. [%]) 
15 (25.0) 26 (61.9) < 0.001
BMI, body mass index; HTN, hypertension; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; BP, blood pressure.
Table 3. Comparisons of initial laboratory and echocardiographic characteristics be-
tween dippers and non-dippers
Parameters Dippers  
(n = 60)
Non-dippers  
(n = 42)
P value
hsCRP (mg/L)    0.93 ± 0.85   1.13 ± 1.28 0.434
Total cholesterol (mg/dL)  195.7 ± 37.5 195.3 ± 35.8 0.957
Triglycerides (mg/dL)    174.8 ± 116.7 152.7 ± 69.5 0.244
HDL-cholesterol (mg/dL)    49.7 ± 13.6   49.2 ± 10.3 0.845
LDL-cholesterol (mg/dL)  118.4 ± 34.8 122.4 ± 34.5 0.578
Initial BUN (mg/dL)  15.0 ± 3.7 13.7 ± 3.3 0.081
Initial creatinine (mg/dL)    0.93 ± 0.19   0.85 ± 0,19 0.050
Initial eGFR (mL/min/1.73 m
2)    80.3 ± 14.4   83.0 ± 18.4 0.397
Urine ACR (mg/g)    19.5 ± 34.5   23.7 ± 34.1 0.561
LV ejection fraction (%)  70.9 ± 6.3 69.4 ± 7.4 0.268
LA volume index (mL/m
2)
  20.5 ± 5.2 24.3 ± 7.3 < 0.01
E/E’    9.65 ± 2.29 12.42 ± 3.88 < 0.001
Presence of LVH (No. [%]) 2 (3.3) 6 (14.3) < 0.05
hsCRP, high sensitivity C-reactive protein; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration 
rate; ACR, albumin/creatinine ratio; LV, left ventricle; LA, left atrium; LVH, left ventricu-
lar hypertrophy.An HR, et al.  •  Non-Dipper and LVH as Predictors of Incident CKD
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CKD and without CKD. However, the proportion of non-dippers 
was significantly higher in patients with CKD than in patients 
without CKD (72.7% vs 37.4%, P < 0.05). Patients with newly de-
veloped CKD revealed a lower HDL-cholesterol (41.7 ± 8.3 mg/
dL vs 50.4 ± 12.4 mg/dL, P < 0.05) and higher urine ACR (52.3 ± 
58.6 mg/g vs 17.8 ± 29.3 mg/g, P < 0.01) and a higher proportion 
of patients with LVH (27.3% vs 5.5%, P < 0.05) compared with 
patients without CKD.  
Predictors of the development of CKD
Univariate Cox regression analysis revealed that the duration of 
hypertension (hazard ratio [HR], 1.09; 95% confidence interval 
[CI], 1.00-1.18), non-dipper status (HR 7.90; 95% CI, 2.02-30.91), 
E/E’ (HR 1.27; 95% CI, 1.08-1.48), and LVH (HR 6.85; 95% CI, 1.81-
25.93) were significant for CKD development. However, age, 
gender, BMI, smoking history, office BP, mean BP measured by 
24-hr ABPM, initial eGFR, urine ACR, LV ejection fraction, and 
LA volume index were not significantly related to the develop-
ment of CKD. Further adjustments revealed that non-dipper 
status and LVH remained robust as significant predictors of in-
cident CKD. Non-dipper status (HR 30.76; 95% CI, 1.75-542.12) 
and LVH (HR 175.97; 95% CI, 4.03-7679.90) were independent 
predictors of incident CKD when adjustments were made for 
age, gender, office BP, duration of hypertension, initial eGFR, 
urine ACR and E/E’ (Table 4).
DISCUSSION
In the present study, we demonstrated that patients with newly 
developed CKD, whose eGFR was reduced < 60 mL/min per 1.73 
m
2 and persisted for more than 3 months, were significantly more 
frequent in the non-dippers on 24-hr ABPM in non-diabetic 
hypertensive patients. In addition, non-dipper status and LVH 
were predictors of incident CKD in non-diabetic hypertensive 
patients independent of office BP or mean fulltime/daytime BP. 
  In epidemiologic studies, age, gender, ethnicity, diabetes, hy-
pertension, vascular diseases, obesity, smoking, low HDL-cho-
lesterol level, and a mild reduction in GFR were important risk 
factors for new-onset CKD (3, 4). Because a considerable portion 
of participants in those epidemiologic studies had diabetes, met-
abolic syndrome, and other risk factors for vascular diseases, 
determinants for incident CKD in low-risk, non-diabetic hyper-
tensive patients still remain for evaluation. In the present study, 
none of the participants had diabetes, macroalbuminuria and 
any form of vascular diseases. Therefore, the participants in this 
study were considered to have a low probability for the develop-
ment of CKD.
  Although it is generally agreed that hypertension exacerbates 
all forms of CKD and accelerates progression to ESRD, the epi-
demiologic evidence supporting mild-to-moderate essential hy-
pertension as an initiator of kidney damage has been weak (17). 
Along these lines, it has been reported that only ‘genetically sus-
ceptible’ patients with hypertension will develop CKD (18). In 
the current study, the non-dipping pattern on 24-hr ABPM and 
LVH on echocardiography, which could be easily confirmed at 
the bedside, was identified as predictors of new-onset CKD.   
  The relationship between the non-dipping phenomenon and 
existing CKD has been previously reported. Non-dipping is sig-
nificantly more prevalent in patients with underlying renal dis-
ease, and the prevalence increases with worsening renal func-
tion in up to 80% of ESRD patients (19). The nocturnal fall in BP 
is attenuated in patients with polycystic kidney disease or IgA 
nephropathy (20, 21). In diabetic patients, a blunted nocturnal 
fall in BP is closely associated with albuminuria (22). Further-
more, the non-dipping phenomenon is associated with a faster 
progression of renal insufficiency in pre-dialysis CKD patients 
(6), and an increased risk of total mortality and the composite 
end point of incident ESRD and death in a cohort study of vet-
erans with CKD (23). 
  LVH was a predictor for subsequent renal dysfunction in high-
risk hypertensive patients in a recent epidemiologic study (13), 
as well as an epiphenomenon in hypertensive patients and a 
risk factor for cardiovascular events. A cross-sectional analysis 
revealed that renal dysfunction defined as creatinine clearance 
< 60 mL/min/1.73 m
2 or microalbuminuria was independently 
related to the presence of LVH (24). In accordance with previous 
studies, LVH was a potent factor for predicting incident CKD in 
this study. 
  Increased LV mass is often accompanied by diastolic dysfunc-
tion and thus the diagnosis of diastolic heart failure can be made 
on the basis of LVH, clinical evidence of heart failure, and a nor-
mal LV ejection fraction (25). The ratio of mitral velocity to early 
diastolic velocity of the mitral annulus (E/E’) reflects diastolic 
function (26). In the present study, E/E’ was also significantly 
correlated with the presence of LVH (data not shown), and E/E’ 
was a potential predictor for incident CKD based on univariate 
analysis, but not statistically significant on multivariate Cox re-
gression analysis. It is likely because the subjects had a low prev-
alence of diastolic heart failure with symptoms and E/E’ > 15. 
Table 4. Non-dipper status and LVH as independent predictors of incident chronic 
kidney disease 
Disease models   HR   95% CI  P value
Model 1
   Non-dipper
   LVH
 
    7.25
    9.31
 
1.34-39.08
1.30-66.76
 
< 0.05
< 0.05
Model 2
   Non-dipper
   LVH
 
  12.80
  60.34
 
  1.42-115.13
    3.12-1166.11
 
< 0.05
< 0.01
Model 3
   Non-dipper
   LVH
 
  30.76
175.97
 
  1.75-542.12
    4.03-7679.90
 
< 0.05
< 0.01
Model 1, adjusted for age, gender, office BP and duration of hypertension; Model 2, 
model 1 plus initial eGFR and urine ACR; Model 3, model 2 plus E/E’.An HR, et al.  •  Non-Dipper and LVH as Predictors of Incident CKD
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  In addition, dyslipidemia is thought to be a risk factor for the 
development of CKD. Subjects with an elevated ratio of LDL- to 
HDL-cholesterol had a faster decline, and both the lipoprotein 
ratio and HDL-cholesterol level were significant risk factors (27). 
In the Atherosclerosis Risk in Communities (ARIC) study, indi-
viduals with higher triglycerides and lower HDL-cholesterol at 
baseline were independent risk factors for a rise in creatinine 
(28). In the current study, we also showed that patients with new-
onset CKD had lower HDL-cholesterol; however, the relationship 
did not reach statistical significance in a Cox regression model. 
  In contrast to previous results (3), age, BMI, smoking, and 
eGFR were not significant predictors of incident CKD in the pres-
ent study. Although, the initial eGFR was significantly lower in 
patients with new-onset CKD than in patients without CKD, it 
did not reach statistical significance based on Cox regression 
analysis. In addition, the rate of decline in eGFR was also higher 
in incident CKD patients compared with patients without CKD. 
Therefore, patients with incident CKD might have characteris-
tics other than a lower initial eGFR.     
  There were some limitations to the present study. Only one 
assessment of 24-hr ABPM was performed in all patients at base-
line. Despite the difference in baseline renal function of the par-
ticipants, the consistency in circadian BP variation was reported 
to be poor in CKD stages 3-5 and single measurements of 24-hr 
ABPM were probably inadequate for the evaluation of dipping 
status (29). In addition, because it was a retrospective study, anti-
hypertensive medications during the follow-up period were not 
equally controlled. Furthermore, uniform intervention of use in 
antihypertensive medications was not performed; therefore we 
could not evaluate the effect of different usage of various anti-
hypertensives. Finally, we could not compare other outcomes 
according to dipper status, such as cardiovascular morbidity and 
mortality, with the exception of renal outcomes, due to the rela-
tively small size and short follow-up periods. 
  In conclusion, although the mechanism for the relationship 
between the non-dipping phenomenon and decline in renal 
function is not clearly understood in the present study, a non-
dipping pattern on 24-hr ABPM and LVH are independent pre-
dictors of incident CKD in hypertensive patients without diabe-
tes and other vascular diseases. These findings suggest that non-
dipper status and LVH may be the therapeutic targets for pre-
venting the development of CKD in non-diabetic hypertensive 
patients.
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